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http://dx.doi.org/10.1016/j.fjs.2013.Summary Human bone marrow-derived mesenchymal stem cells (MSCs) have emerged as a
promising tool for clinical applications, which require developing techniques and protocols
of cell expansion to overcome cell senescence, loss of pluripotent gene expression, decrease
in self-renewal and differentiation potential, low engraftment after in vivo transplantation,
and rejection by allogeneic recipients. Moreover, the expanded cells should have normal kar-
yotype and genome integrity to prevent tumorigenic transformation. Cultivation of MSCs under
hypoxic conditions, the normal physiologic status of bone marrow, represents a new platform
of MSC expansion for clinical applications. This article reviews the effects of hypoxic culture on
MSCs, especially for translation from bench to bedside, emphasizing hypoxia as an important
factor in all of the major aspects of MSC biology.
Copyright ª 2013, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Mesenchymal stem cells (MSCs) are the best studied sub-
populations of stem/progenitor cells in bonemarrowcapable
of differentiating into various nonhematopoietic cells, and
they are isolated by their adherence to tissue culture
surfaces.1e4 They are readily isolated from patients, theyd Education, Taipei Veterans Gen
v.tw.
ight ª 2013, Taiwan Surgical Asso
03.001can be expanded in culture with maintained differentiation
potential and immune-modulating properties, and they
have a limited tendency to form tumors. Thus, MSCs have
emerged as a promising tool for clinical applications such as
tissue engineering and cell-based therapy. The first stem cell
drug in the world has just been approved in Canada to treat
acute graft-versus-host disease in allogeneic recipients.eral Hospital, 201, Section 2, Shih-Pai Road, Taipei 11217, Taiwan.
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Because the therapeutic potential of MSCs has generated
remarkably increasing interest in a wide variety of
biomedical disciplines and because of the increasing diffi-
culties to compare outcomes, the International Society for
Cellular Therapy has proposed minimal criteria to define
human MSCs. Thus, MSCs expanded for clinical applications
should meet all of the criteria.5 Firstly, MSCs must be
adherent to plastic when maintained in standard culture
conditions. Secondly, MSCs must express CD105, CD73, and
CD90, and lack expression of CD45, CD34, CD14 or CD11b,
CD79-alpha or CD19, and human leukocyte antigen (HLA)-
DR surface molecules. Thirdly, MSCs must possess the
ability to differentiate into osteoblasts, adipocytes, and
chondroblasts in vitro.
3. Problems encountered during clinical
application
There are several problems associated with the clinical
application of MSCs (Table 1). For clinical applications, these
cells should be expanded to a large scale with a gold-
standard protocol without undergoing senescence or loss of
proliferation capacity. Moreover, the expanded cells should
meet the criteria for MSCs, maintain the expression of plu-
ripotency genes and the potential for differentiation, and
engraft or regenerate the tissues following transplantation
into autologous or allogeneic recipients. Since MSC-derived
microvesicles have been proposed to protect patients
against injuries, such as renal injury in the mouse remnant
kidney model,6 the real roles of MSCs in contributing thera-
peutic effects in injuries should be clarified prior to clinical
application. More importantly, the processing procedures or
the facility used for cell manipulation or expansion should be
regulated and approved to provide products that pass tests
regarding identity, potency, purity, and safety of cell prod-
ucts [United States Pharmacopeia 32 (1046)].Table 1 Challenges encountered during clinical applica-
tions of human mesenchymal stem cells.
Expansion or scale up
No standard protocol
Following expansion: senescence and loss of proliferation
Phenotypes and functions
Lack of pluripotency gene expression
Loss of (trans-)differentiation and repairing ability
Decrease in “paracrine effects”
In vivo transplantation
Low engraftment and differentiation rate after
transplantation
Rejection after allogeneic transplantation (HLA
mismatch)
Safety and regulation issues
Identify test
Potency test
Purity test
Safety test
HLA Z human leukocyte antigen.4. Hypoxic niche
The bone marrow niche facilitates the maintenance of
hematopoietic stem cells (HSCs) as undifferentiated while
supporting the lineage commitment of the expanding blood
populations.7 MSCs that reside in the bone marrow, are
associated with and maintain HSCs functions, give rise to
mesenchymal-committed cells such as osteoblasts and
adipocytes for maintaining bone structures. Bone marrow is
hypoxic and has an oxygen tension around 1e7%.8,9 Because
the general culture condition of 21% oxygen within an
incubator is hyperoxic compared with the normal niche of
MSCs, one of the strategies to solve the problems encoun-
tered upon clinical application of MSCs is expanding these
cells under hypoxic conditions. Thus, the roles of the bone
marrow niche in maintaining MSC properties and functions
should be well investigated. To understand the effects of
the marrow niche on MSC properties and functions, we and
other groups10,11 cultured MSCs under hypoxic conditions
and compared them with those cultured under normoxic
conditions. Most studies have demonstrated that MSCs
cultured under hypoxia or absolute hypoxia fulfill the
criteria for defining MSCs5 without undergoing apoptosis or
changing immunophenotypes.10,11 This article discusses the
effects of hypoxic culture on the properties of MSCs,
especially for translation from bench to bedside.
5. Effects of hypoxic culture on expansion and
life span
The effects of hypoxic culture on MSC proliferation and
expansion efficiency depend on the sources of derived MSCs,
the oxygen concentration, the seeding density, and the
duration used to culture the MSCs. Some studies have
found that hypoxia significantly inhibits proliferation,12e16
and others have found that hypoxia increases the prolifera-
tion capacity or increases their life span.10,16e22 We demon-
strated that the effect of hypoxia on proliferation was
inhibited within one passage of culture either at low-density
(10e200 cells/cm2) or at high density (1000e4000 cells/
cm2),13whereas hypoxia significantly increased the expansion
efficiency on long-term expansion ( 60 days) of MSCs at low
density.23 Moreover, hypoxia also inhibited senescence,
increased proliferation, and enhanced in vitro and in vivo
differentiation potential.23 The results of these studies show
that the effects of hypoxia on short-term MSC proliferation
varied and depended on the oxygen tensions, seeding den-
sities, and MSC sources used. However, the beneficial effects
of hypoxia on the long-term expansion of MSCs are consistent
even with different MSC sources at a variety of oxygen
concentrations.10,21,23
6. Effects of hypoxic culture on maintaining
self-renewal and potential differentiation
Stem cell properties, referred to as self-renewal and dif-
ferentiation potential, are prerequisites for success in stem
cell applications. Low-density culture under normoxic
conditions provides a method for rapid expansion of MSCs24
with the loss of proliferation capacity and the gain of cell
Effects of hypoxic culture on MSCs 37senescence.23,25 Furthermore, the long-term expansion of
MSCs under normoxic conditions adversely affects stem-cell
function when protecting the myocardium.26 By contrast,
low-density culture combined with hypoxic culture main-
tains proliferation as well as potential differentiation, it
increases the expression of pluripotent genes, such as Oct4,
Nanog, and Sox2,27 and it inhibits senescence.23 Similarly,
MSCs with hypoxic preconditioning have been shown to in-
crease in the lineage differentiation into bone,28 fat, and
cartilage29 both in vitro and in vivo.23 Increased telomere
length and telomerase activity, normal karyotyping, and
chromosome integration have also been observed.23 More-
over, MSCs with long-term hypoxic preconditioning do not
form tumors when transplanted into immunodeficient mice,
suggesting that hypoxic culture provides a method for
efficiently expanding MSCs without losing stemness27,30 or
increasing tumorigenicity.7. Effects of hypoxic culture on engraftment
The ability of stem or progenitor cells to home and engraft
into target tissues after transplantation is the key to suc-
ceed in clinical application. The degree of homing and
engraftment of MSCs adult recipients is very low.31e33
Interestingly, it has been demonstrated that a 1-day expo-
sure of MSCs to 1% oxygen increased in vitro migration and
in vivo engraftment via the increase of CX3C chemokine
receptor 1 (CX3CR1)-fractalkine and CXC chemokine re-
ceptor4-stromal derived factor-1 (CXCR4-SDF-1)-alpha
interaction.13 MSCs cultured under hypoxic conditions also
increased in vascular endothelial growth factor receptor 1
(VEGFR1) expression and VEGF- or placental growth factor
(PLGF)-dependent migration.34 Preconditioning with
oxygen and combined glucose depletion also increased
the survival of stem cell antigen (Sca)-1þ cells via
phosphatidylinositol 3-OH kinase (PI3K)/Protein kinase B
(also known as Akt)-dependent caspase-3 downregulation
and thereby increased the engraftment rate.35 In addition to
the increase in migration and survival, MSCs with hypoxic
preconditioning have also been shown to enhance revascu-
larization after transplantation for hind limb ischemia.36
These results suggest that short-term hypoxic pre-
conditioning of MSCs may provide a general method of
enhancing their survival, migration, angiogenesis, and
engraftment in vivo into a variety of tissues.8. Effects of hypoxic culture on allogeneic
transplantation
Use of MSCs from healthy donors as an “off-the-shelf”
product has proven safe in two Phase III studies in patients
with graft-versus-host disease and Crohn’s disease (http://
www.clinicaltrails.gov/). Moreover, allogeneic MSCs were
also reported to improve ejection fractions in patients with
acute myocardial infarction.37 The immunosuppressive
features of human, baboon, and murine MSCs were also
reported in vitro,38e41 in vivo,41 and attenuating graft-
versus-host disease in humans.42 However, many studies
have demonstrated allogeneic MSCs were rejected in
immunocompetent MHC-mismatched recipients.43e45 Thus,the use of MSCs for allogeneic transplantation remains
controversial. Thus, identifying methods for enhancing
immunoprivilege in MSCs can help these cells serve as a
“universal donor cell” for treating diseases. A previous
study demonstrated that allogeneic hypoxic MSCs increase
the therapeutic effects in bone defect repair compared
with allogeneic normoxic MSCs.46 These results suggest that
hypoxic MSCs are intrinsically immunoprivileged and can
serve as a “universal donor cell” for treating diseases.
9. Conclusion
Altogether, the studies currently available suggest that
hypoxic cultures have multiple effects on MSCs, which
affect short-term proliferation, long-term expansion effi-
ciency, differentiation potential, stemness or maintenance
of stem cell properties, the expression of chemokine
receptors, migration, and engraftment ability. Moreover,
MSCs can survive and engraft in allogeneic recipients. The
platform based on hypoxic culture will help develop stra-
tegies for clinical applications of MSCs.
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